AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.27+4.14 (+1.04%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.27+4.14 (+1.04%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|
20.4 C
New York
Monday, June 29, 2026

Tag: patients

newssourceFORcompanyinformationcontent1releasesmarket

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Aidoc Secures $150M for CARE, its Healthcare Foundation Model, to Transform Clinical Decision-Making for 100 Million Patients

The Era of Clinical AI Has Arrived: Trusted by Leading Health Systems, Aidoc's Platform Brings AI to the Heart of Patient Care NEW YORK, July 23,...

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

- XIPERE Now Approved for Use in Multiple Global Markets -

The Power of Massage Therapy for Autoimmune Diseases: AMTA Highlights Emerging Research

EVANSTON, Ill., July 23, 2025 /PRNewswire/ -- The American Massage Therapy Association (AMTA) is committed to advancing integrative health care by spotlighting the powerful role...

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Singapore-Based Innovative Biomedical Start-Up Achieves ‘Strategic Triumph’ to Conquer Chinese Med-Tech Market

NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China...

Singapore-Based Innovative Biomedical Start-Up Achieves ‘Strategic Triumph’ to Conquer Chinese Med-Tech Market

NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China...

Cytovation to Advance Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling Under International Nonproprietary Name of Getacatetide

Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has approved "getacatetide" as the International Nonproprietary Name (INN) of CY-101.

Ipsen announces changes to its Executive Committee

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

Global Times: Chinese film veterans inspired by Xi’s reply letter vow to create art rooted in real life

BEIJING, July 22, 2025 /PRNewswire/ -- Editor's Note: Chinese people believe that letters are as valuable as gold. For thousands of years, letters, across mountains...

Heartflow Plaque Analysis to be Covered by UnitedHealthcare Plans Nationwide

Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients 
Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients

Micro Medical Solutions Appoints George Quinoy as President & CEO to Accelerate Commercialization and Drive Value Creation

WOBURN, Mass., July 22, 2025 /PRNewswire/ -- Micro Medical Solutions (MMS), a leading innovator in minimally invasive vascular solutions for Critical Limb Ischemia (CLI),...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers